TScan Therapeutics, Inc.
TCRX
$0.95
-$0.07-6.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -19.48% | -16.71% | -13.22% | -82.58% | -29.96% |
| Total Depreciation and Amortization | -25.32% | -37.46% | -45.93% | -44.45% | -20.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 132.43% | 21.71% | 29.88% | 217.25% | -8.13% |
| Change in Net Operating Assets | -28.67% | -82.32% | -202.70% | 184.85% | -100.98% |
| Cash from Operations | -16.28% | -26.85% | -28.42% | -15.34% | -448.24% |
| Capital Expenditure | -4.01% | -48.38% | -117.30% | -89.34% | 3.45% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 141.99% | 251.32% | -59.15% | 1,083.08% | -34.98% |
| Cash from Investing | 139.56% | 243.66% | -62.59% | 1,326.71% | -34.09% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -99.43% | -- | 1,889.47% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.06% | -- | -- | 100.00% |
| Cash from Financing | -100.00% | -99.93% | -303.49% | 240,373.68% | 588.10% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 100.10% | -84.96% | -443.60% | 308.72% | -103.25% |